{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:31Z","timestamp":1786996771480,"version":"build-2736575974"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,12]],"date-time":"2027-01-12T00:00:00Z","timestamp":1799712000000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018896","name":"Sylvester Comprehensive Cancer Center, University of Miami Health Systems","doi-asserted-by":"publisher","award":["TB-INTRA-2024-03"],"award-info":[{"award-number":["TB-INTRA-2024-03"]}],"id":[{"id":"10.13039\/100018896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006827","name":"Florida Department of Health","doi-asserted-by":"publisher","award":["23L12"],"award-info":[{"award-number":["23L12"]}],"id":[{"id":"10.13039\/100006827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008530","name":"University of Miami School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX-24-001"],"award-info":[{"award-number":["BX-24-001"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["KC210133"],"award-info":[{"award-number":["KC210133"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.semcancer.2025.12.010","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:12:20Z","timestamp":1767773540000},"page":"54-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Lipid dysregulation in renal cancer: Drivers of tumor growth and determinants of treatment-induced toxicity"],"prefix":"10.1016","volume":"119","author":[{"given":"Mohammed","family":"Alnukhali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fornoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anis","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semcancer.2025.12.010_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/ijms23010151","article-title":"Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC)","volume":"23","author":"Rysz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.humpath.2013.08.004","article-title":"Clear cell papillary renal cell carcinoma is the fourth most common histologic type of renal cell carcinoma in 290 consecutive nephrectomies for renal cell carcinoma","volume":"45","author":"Zhou","year":"2014","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib4","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/s41467-017-01965-8","article-title":"HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism","volume":"8","author":"Du","year":"2017","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.semcancer.2025.12.010_bib5","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.biocel.2007.04.025","article-title":"Distal tubular epithelial cells of the kidney: Potential support for proximal tubular cell survival after renal injury","volume":"39","author":"Gobe","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"10","key":"10.1016\/j.semcancer.2025.12.010_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41581-023-00741-w","article-title":"Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease","volume":"19","author":"Mitrofanova","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.12.010_bib7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1128\/MCB.01441-13","article-title":"Loss of von Hippel-Lindau protein (VHL) increases systemic cholesterol levels through targeting hypoxia-inducible factor 2\u03b1 and regulation of bile acid homeostasis","volume":"34","author":"Ramakrishnan","year":"2014","journal-title":"Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.12.010_bib8","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3390\/biomedicines11082163","article-title":"Hypoxic state of cells and immunosenescence: a focus on the role of the hif signaling pathway","volume":"11","author":"Troise","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00240-4","article-title":"Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth","volume":"3","author":"Mack","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2025.12.010_bib10","doi-asserted-by":"crossref","first-page":"g4797","DOI":"10.1136\/bmj.g4797","article-title":"Renal cell carcinoma","volume":"349","author":"Jonasch","year":"2014","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.semcancer.2025.12.010_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1302\/2058-5241.2.170006","article-title":"Diagnostic algorithm, prognostic factors and surgical treatment of metastatic cancer diseases of the long bones and spine","volume":"2","author":"Szendr\u0151i","year":"2017","journal-title":"EFORT Open Rev."},{"issue":"4","key":"10.1016\/j.semcancer.2025.12.010_bib12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2011.01.002","article-title":"Toxicities of Targeted Therapy and Their Management in Kidney Cancer","volume":"59","author":"Di Lorenzo","year":"2011","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.semcancer.2025.12.010_bib13","first-page":"4151","article-title":"Management of nephrotoxicity of chemotherapy and targeted agents: 2020","volume":"10","author":"Chiruvella","year":"2020","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.semcancer.2025.12.010_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16061209","article-title":"Current treatment options for renal cell carcinoma: focus on cell-based immunotherapy","author":"Hwang","year":"2024","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.semcancer.2025.12.010_bib15","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1080\/14712598.2021.1890713","article-title":"Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma","volume":"21","author":"St\u00fchler","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.semcancer.2025.12.010_bib16","first-page":"12","article-title":"Prognostic value of lymph node evaluation in stage ii small bowel adenocarcinoma: an updated analysis of surveillance, epidemiology, and end results database","author":"Liu","year":"2022","journal-title":"Front. Oncol. Vol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.12.010_bib17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3390\/cancers14040953","article-title":"Everything comes with a price: the toxicity profile of DNA-damage response targeting agents","volume":"14","author":"Martorana","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.semcancer.2025.12.010_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1600-0609.2004.00272.x","article-title":"Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure","volume":"73","author":"Tosi","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.semcancer.2025.12.010_bib19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3389\/fphys.2020.00732","article-title":"The vicious cycle of renal lipotoxicity and mitochondrial dysfunction","volume":"11","author":"Ge","year":"2020","journal-title":"Front Physiol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41420-025-02419-7","article-title":"High-fat diet promotes lipotoxicity in the podocytes of uninephrectomized mice: a targeted lipidomics and kidney podocyte-specific analysis","volume":"11","author":"Oh","year":"2025","journal-title":"Cell Death Discov."},{"issue":"7","key":"10.1016\/j.semcancer.2025.12.010_bib21","article-title":"Oxidative stress and lipid dysregulation in lipid droplets: a connection to chronic kidney disease revealed in human kidney Cells","volume":"11","author":"Chen","year":"2022","journal-title":"Antioxid. (Basel)"},{"key":"10.1016\/j.semcancer.2025.12.010_bib22","doi-asserted-by":"crossref","first-page":"1133832","DOI":"10.3389\/fonc.2023.1133832","article-title":"Treatment strategies for clear cell renal cell carcinoma: Past, present and future","volume":"13","author":"Yang","year":"2023","journal-title":"Front Oncol."},{"issue":"14","key":"10.1016\/j.semcancer.2025.12.010_bib23","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.18632\/oncotarget.7939","article-title":"An image guided small animal stereotactic radiotherapy system","volume":"7","author":"Sha","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.semcancer.2025.12.010_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252978","article-title":"Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study","volume":"16","author":"Koks","year":"2021","journal-title":"PLOS ONE"},{"issue":"5","key":"10.1016\/j.semcancer.2025.12.010_bib25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40620-016-0278-5","article-title":"Lipotoxicity as a trigger factor of renal disease","volume":"29","author":"Izquierdo-Lahuerta","year":"2016","journal-title":"J. Nephrol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.12.010_bib26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000488816","article-title":"Disorders of lipid metabolism in chronic kidney disease","volume":"46","author":"Bulbul","year":"2018","journal-title":"Blood Purif."},{"key":"10.1016\/j.semcancer.2025.12.010_bib27","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fonc.2021.727778","article-title":"The uniqueness of clear cell renal cell carcinoma: summary of the process and abnormality of glucose metabolism and lipid metabolism in ccRCC","volume":"11","author":"Qi","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.12.010_bib28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/biof.1187","article-title":"ABCA1 and nascent HDL biogenesis","volume":"40","author":"Wang","year":"2014","journal-title":"Biofactors"},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib29","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1038\/s41598-018-24428-6","article-title":"Temporary sequestration of cholesterol and phosphatidylcholine within extracellular domains of ABCA1 during nascent HDL generation","volume":"8","author":"Ishigami","year":"2018","journal-title":"Sci. Rep."},{"issue":"26","key":"10.1016\/j.semcancer.2025.12.010_bib30","doi-asserted-by":"crossref","first-page":"9774","DOI":"10.1073\/pnas.0403506101","article-title":"ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins","volume":"101","author":"Wang","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"34","key":"10.1016\/j.semcancer.2025.12.010_bib31","doi-asserted-by":"crossref","first-page":"30150","DOI":"10.1074\/jbc.M505368200","article-title":"ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins","volume":"280","author":"Vaughan","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.semcancer.2025.12.010_bib32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1172\/JCI27602","article-title":"HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway","volume":"116","author":"Matsuura","year":"2006","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.semcancer.2025.12.010_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/10668969241256111","article-title":"Clear Cell Renal Cell Carcinoma: A Comprehensive Review of its Histopathology, Genetics, and Differential Diagnosis","volume":"33","author":"Nezami","year":"2025","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.semcancer.2025.12.010_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/17562872241232578","article-title":"The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma","volume":"16","author":"Naik","year":"2024","journal-title":"Ther. Adv. Urol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib35","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1186\/s12889-023-15647-2","article-title":"Trends in cause of death among patients with renal cell carcinoma in the United States: a SEER-based study","volume":"23","author":"Zhan","year":"2023","journal-title":"BMC Public Health"},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.clgc.2018.10.002","article-title":"Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study","volume":"17","author":"Saad","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2025.12.010_bib37","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/ijc.30845","article-title":"Large-scale genome-wide screening of circulating microRNAs in clear cell renal cell carcinoma reveals specific signatures in late-stage disease","volume":"141","author":"Chanudet","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2025.12.010_bib38","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.3390\/ijms21093378","article-title":"Gender-Related Approach to Kidney Cancer Management: Moving Forward","volume":"21","author":"Mancini","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.semcancer.2025.12.010_bib39","first-page":"507","article-title":"Treatment of renal cell carcinoma: Current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib40","article-title":"Laparoscopic Radical Nephrectomy: The New Gold Standard Surgical Treatment for Localized Renal Cell Carcinoma","volume":"7","author":"Eskicorapci","year":"2007","journal-title":"Sci. World J."},{"issue":"4","key":"10.1016\/j.semcancer.2025.12.010_bib41","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol. Clin."},{"key":"10.1016\/j.semcancer.2025.12.010_bib42","first-page":"179","author":"Zheng","year":"2024","journal-title":"Mech. Strateg."},{"key":"10.1016\/j.semcancer.2025.12.010_bib43","series-title":"Receptor Tyrosine Kinases in Cancer, Springer Nature Switzerland, Cham","first-page":"331","article-title":"Future Directions for Receptor Tyrosine Kinases in Cancer Treatment","author":"Sharma","year":"2025"},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cancers17010155","article-title":"Metabolic signaling in the tumor microenvironment","volume":"17","author":"Clay","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41420-025-02479-9","article-title":"The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma","volume":"11","author":"Zhang","year":"2025","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.semcancer.2025.12.010_bib46","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.3390\/ijms24043272","article-title":"Lipids as targets for renal cell carcinoma therapy","volume":"24","author":"Stepanovska Tanturovska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.semcancer.2025.12.010_bib47","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00280-021-04260-y","article-title":"Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function","volume":"87","author":"Mielczarek","year":"2021","journal-title":"Cancer Chemother. Pharm."},{"issue":"2","key":"10.1016\/j.semcancer.2025.12.010_bib48","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11523-023-00951-z","article-title":"Analysis of anti-angiogenesis-related adverse events associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma","volume":"18","author":"Lee","year":"2023","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3390\/biomedicines11010181","article-title":"Cardiotoxicity of selected vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with renal cell carcinoma","volume":"11","author":"Franczyk","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.semcancer.2025.12.010_bib50","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor\u2013associated nephritis\u2014treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"issue":"8","key":"10.1016\/j.semcancer.2025.12.010_bib51","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int. Rep."},{"issue":"9","key":"10.1016\/j.semcancer.2025.12.010_bib52","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1172\/JCI85939","article-title":"Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury","volume":"126","author":"Pedigo","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.semcancer.2025.12.010_bib53","first-page":"2024","article-title":"Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.12.010_bib54","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/ehf2.15281","article-title":"Immune Checkpoint Inhibitors and Cardiovascular Adverse Events","volume":"12","author":"De Perna","year":"2025","journal-title":"ESC Heart Fail."},{"issue":"19","key":"10.1016\/j.semcancer.2025.12.010_bib55","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.3390\/cancers14194693","article-title":"The emerging role of radiation therapy in renal cell carcinoma","volume":"14","author":"Christensen","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.semcancer.2025.12.010_bib56","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ucl.2023.01.008","article-title":"Radiation therapy in the treatment of localized and advanced renal cancer","volume":"50","author":"Yim","year":"2023","journal-title":"Urol. Clin."},{"issue":"4","key":"10.1016\/j.semcancer.2025.12.010_bib57","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jemt.10072","article-title":"Podocyte is the major culprit accounting for the progression of chronic renal disease","volume":"57","author":"Kriz","year":"2002","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.semcancer.2025.12.010_bib58","doi-asserted-by":"crossref","first-page":"12718","DOI":"10.3390\/cimb46110755","article-title":"Molecular insights into radiation effects and protective mechanisms: a focus on cellular damage and radioprotectors","author":"Ib\u00e1\u00f1ez","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1-2","key":"10.1016\/j.semcancer.2025.12.010_bib59","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2011.12.012","article-title":"Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury","volume":"327","author":"Azzam","year":"2012","journal-title":"Cancer Lett."},{"issue":"23","key":"10.1016\/j.semcancer.2025.12.010_bib60","doi-asserted-by":"crossref","first-page":"14786","DOI":"10.3390\/ijms232314786","article-title":"Tissue reactions and mechanism in cardiovascular diseases induced by radiation","volume":"23","author":"Liu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2025.12.010_bib61","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3389\/fmicb.2017.00793","article-title":"Reactive oxygen species-mediated cellular stress response and lipid accumulation in oleaginous microorganisms: the state of the art and future perspectives","volume":"8","author":"Shi","year":"2017","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.semcancer.2025.12.010_bib62","series-title":"Oxidative Stress: Human Diseases and Medicine","first-page":"213","article-title":"Reactive Oxygen Species, Glucose Metabolism, and Lipid Metabolism","author":"Yang","year":"2021"},{"issue":"9","key":"10.1016\/j.semcancer.2025.12.010_bib63","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.3168\/jds.2021-21774","article-title":"Low abundance of mitophagy markers is associated with reactive oxygen species overproduction in cows with fatty liver and causes reactive oxygen species overproduction and lipid accumulation in calf hepatocytes","volume":"105","author":"Fang","year":"2022","journal-title":"J. Dairy Sci."},{"issue":"4","key":"10.1016\/j.semcancer.2025.12.010_bib64","doi-asserted-by":"crossref","first-page":"383","DOI":"10.21147\/j.issn.1000-9604.2016.04.01","article-title":"Overproduction of reactive oxygen species - obligatory or not for induction of apoptosis by anticancer drugs","volume":"28","author":"Ivanova","year":"2016","journal-title":"Chin. J. Cancer Res"},{"issue":"8","key":"10.1016\/j.semcancer.2025.12.010_bib65","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.bcp.2008.11.009","article-title":"Reactive oxygen species: destroyers or messengers?","volume":"77","author":"Bartosz","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.12.010_bib66","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.freeradbiomed.2011.06.022","article-title":"Uncoupling proteins and the control of mitochondrial reactive oxygen species production","volume":"51","author":"Mailloux","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.semcancer.2025.12.010_bib67","series-title":"Reactive oxygen species (ROS), nanoparticles, and endoplasmic reticulum (er) stress-induced cell death mechanisms","author":"Madkour","year":"2020"},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib68","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s44371-025-00275-z","article-title":"Reactive oxygen species (ROS): Sources, generation, disease pathophysiology, and antioxidants","volume":"2","author":"Ansari","year":"2025","journal-title":"Discov. Chem."},{"issue":"4","key":"10.1016\/j.semcancer.2025.12.010_bib69","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.3390\/ijms24044004","article-title":"Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation","volume":"24","author":"Antar","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13014-021-01764-y","article-title":"Radiation-induced kidney toxicity: molecular and cellular pathogenesis","volume":"16","author":"Klaus","year":"2021","journal-title":"Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.12.010_bib71","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00467-015-3169-4","article-title":"Tubular atrophy in the pathogenesis of chronic kidney disease progression","volume":"31","author":"Schelling","year":"2016","journal-title":"Pediatr. Nephrol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-5876-9-13","article-title":"Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications","volume":"9","author":"L\u00f3pez-Novoa","year":"2011","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2025.12.010_bib73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","article-title":"Pazopanib: clinical development of a potent anti-angiogenic drug","volume":"77","author":"Schutz","year":"2011","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib74","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-016-0374-y","article-title":"New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy","volume":"10","author":"Zarrabi","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2025.12.010_bib75","first-page":"443","article-title":"Pazopanib","author":"Keisner","year":"2011","journal-title":"Drugs 71(4"},{"issue":"6","key":"10.1016\/j.semcancer.2025.12.010_bib76","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3390\/cancers14061406","article-title":"Angiogenesis inhibitors and immunomodulation in renal cell cancers: the past, present, and future","volume":"14","author":"Kasherman","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2025.12.010_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040869","article-title":"Abnormal crosstalk between endothelial cells and podocytes mediates tyrosine kinase inhibitor (TKI)-induced nephrotoxicity","author":"Gu","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.semcancer.2025.12.010_bib78","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-981-13-8871-2_10","article-title":"Role of podocyte injury in glomerulosclerosis","volume":"1165","author":"Lu","year":"2019","journal-title":"Adv. Exp. Med Biol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.12.010_bib79","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4239\/wjd.v12.i5.524","article-title":"New insights into renal lipid dysmetabolism in diabetic kidney disease","volume":"12","author":"Mitrofanova","year":"2021","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.semcancer.2025.12.010_bib80","doi-asserted-by":"crossref","first-page":"1017921","DOI":"10.3389\/fneph.2022.1017921","article-title":"Immune checkpoint inhibitor related nephrotoxicity: advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge","volume":"2","author":"Miao","year":"2022","journal-title":"Front Nephrol."},{"key":"10.1016\/j.semcancer.2025.12.010_bib81","article-title":"Immunotherapies and renal injury","volume":"31","author":"Shaikh","year":"2022","journal-title":"Curr. Opin. Toxicol."},{"key":"10.1016\/j.semcancer.2025.12.010_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102282","article-title":"Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors","volume":"100","author":"Arangalage","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.semcancer.2025.12.010_bib83","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00592-015-0753-9","article-title":"Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy","volume":"52","author":"Zhang","year":"2015","journal-title":"Acta Diabetol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.12.010_bib84","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/antiox9080752","article-title":"Chronic Kidney disease as oxidative stress- and inflammatory-mediated cardiovascular disease","volume":"9","author":"Podkowi\u0144ska","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.semcancer.2025.12.010_bib85","first-page":"2018","article-title":"Glomerular endothelial cell stress and cross-talk with podocytes in early diabetic kidney disease","volume":"5","author":"Daehn","year":"2018","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib86","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-021-09996-w","article-title":"Lipid metabolism reprogramming in renal cell carcinoma","volume":"41","author":"Heravi","year":"2022","journal-title":"Cancer Metastas.. Rev."},{"issue":"7","key":"10.1016\/j.semcancer.2025.12.010_bib87","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrneph.2017.59","article-title":"Metabolic reprogramming in clear cell renal cell carcinoma","volume":"13","author":"Wettersten","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib88","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41420-025-02479-9","article-title":"The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma","volume":"11","author":"Zhang","year":"2025","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib89","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.semcancer.2012.06.002","article-title":"The metabolic basis of kidney cancer","volume":"23","author":"Linehan","year":"2013","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib90","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12944-021-01572-z","article-title":"Revealing potential lipid biomarkers in clear cell renal cell carcinoma using targeted quantitative lipidomics","volume":"20","author":"Li","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.semcancer.2025.12.010_bib91","series-title":"Advances in Cancer Research","first-page":"77","article-title":"Chapter Three - Nephrotoxicity in cancer treatment: An update","author":"Chen","year":"2022"},{"key":"10.1016\/j.semcancer.2025.12.010_bib92","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1656053","article-title":"An overview of lipid droplets in cancer and cancer stem cells","author":"Tirinato","year":"2017","journal-title":"Stem Cells Int 2017"},{"key":"10.1016\/j.semcancer.2025.12.010_bib93","first-page":"349","article-title":"Fatty Acid Uptake and Lipid Storage Induced by HIF-1\u03b1; Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation","volume":"9","author":"Bensaad","year":"2014"},{"issue":"7","key":"10.1016\/j.semcancer.2025.12.010_bib94","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1681\/ASN.2015020190","article-title":"Megalin-mediated tubuloglomerular alterations in high-fat diet-induced kidney disease","volume":"27","author":"Kuwahara","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib95","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12943-025-02457-w","article-title":"Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting","volume":"24","author":"Deng","year":"2025","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2025.12.010_bib96","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3803\/EnM.2023.1915","article-title":"Lipid variability induces endothelial dysfunction by increasing inflammation and oxidative stress","volume":"39","author":"Rhee","year":"2024","journal-title":"Endocrinol. Metab. (Seoul. )"},{"issue":"4","key":"10.1016\/j.semcancer.2025.12.010_bib97","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1152\/physrev.00005.2005","article-title":"ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease","volume":"85","author":"Oram","year":"2005","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.semcancer.2025.12.010_bib98","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jphs.2022.07.004","article-title":"HDL, cholesterol efflux, and ABCA1: free from good and evil dualism","volume":"150","author":"Ogura","year":"2022","journal-title":"J. Pharmacol. Sci."},{"issue":"12","key":"10.1016\/j.semcancer.2025.12.010_bib99","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jacbts.2024.08.005","article-title":"ABCA1-Super Enhancer RNA promotes cholesterol efflux, reduces macrophage-mediated inflammation and atherosclerosis","volume":"9","author":"Wang","year":"2024","journal-title":"JACC Basic Transl. Sci."},{"issue":"7","key":"10.1016\/j.semcancer.2025.12.010_bib100","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med"},{"key":"10.1016\/j.semcancer.2025.12.010_bib101","doi-asserted-by":"crossref","first-page":"1331671","DOI":"10.3389\/fonc.2023.1331671","article-title":"The renal damage and mechanisms relevant to antitumoral drugs","volume":"13","author":"Tang","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.semcancer.2025.12.010_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17030288","article-title":"Cyclodextrins: enhancing drug delivery, solubility and bioavailability for modern therapeutics","author":"Nicolaescu","year":"2025","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.semcancer.2025.12.010_bib103","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1194\/jlr.M700254-JLR200","article-title":"The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential","volume":"49","author":"Zanotti","year":"2008","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.semcancer.2025.12.010_bib104","doi-asserted-by":"crossref","first-page":"1700313","DOI":"10.1002\/adhm.201700313","article-title":"Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr \u2212\/\u2212 Mice","volume":"6","author":"Yu","year":"2017","journal-title":"Adv. Healthc. Mater."},{"issue":"5","key":"10.1016\/j.semcancer.2025.12.010_bib105","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1194\/jlr.M033977","article-title":"LXR activation by GW3965 alters fat tissue distribution and adipose tissue inflammation in ob\/ob female mice","volume":"54","author":"Archer","year":"2013","journal-title":"J. Lipid Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.12.010_bib106","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1038\/s41467-021-24890-3","article-title":"Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease","volume":"12","author":"Wright","year":"2021","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.semcancer.2025.12.010_bib107","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1681\/ASN.0000000000000212","article-title":"Podocyte injury in diabetic kidney disease in mouse models involves TRPC6-mediated Calpain activation impairing autophagy","volume":"34","author":"Salemkour","year":"2023","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.12.010_bib108","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41419-024-06627-4","article-title":"TRIB3 promotes the progression of renal cell carcinoma by upregulating the lipid droplet-associated protein PLIN2","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2025.12.010_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118615","article-title":"The dual role of lipids in chronic kidney disease: pathogenic culprits and therapeutic allies","volume":"398","author":"Giardini","year":"2024","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.semcancer.2025.12.010_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11080820","article-title":"Use of lipid-modifying agents for the treatment of glomerular diseases","volume":"11","author":"Ge","year":"2021","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.semcancer.2025.12.010_bib111","article-title":"Lipidomic signatures as predictive biomarkers for early-onset lung cancer: identification and development of a risk prediction model","author":"Wang","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.semcancer.2025.12.010_bib112","doi-asserted-by":"crossref","first-page":"1125905","DOI":"10.3389\/fimmu.2023.1125905","article-title":"Mechanistic rationales for combining immunotherapy with radiotherapy","volume":"14","author":"Chi","year":"2023","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.12.010_bib113","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/15384101.2022.2042777","article-title":"Molecular mechanisms for ABCA1-mediated cholesterol efflux","volume":"21","author":"Chen","year":"2022","journal-title":"Cell Cycle"},{"issue":"6","key":"10.1016\/j.semcancer.2025.12.010_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12061010","article-title":"Role of ABCA1 in cardiovascular disease","volume":"12","author":"Wang","year":"2022","journal-title":"J. Pers. Med"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X26000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:01:18Z","timestamp":1773968478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X26000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":114,"alternative-id":["S1044579X26000088"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.12.010","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid dysregulation in renal cancer: Drivers of tumor growth and determinants of treatment-induced toxicity","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}